Entirety to plant millions for Orthopedic Fixation

Introduction

Entirety Biomedical is a medical device startup known for polishing expertise in establishing bioabsorbable magnesium implants mainly for orthopedic surgery. The Curasorb is one of the exclusive magnesium alloys of the company, which is an apt and convincing replacement for stainless steel and permanent titanium hardware for the surgical fixation. The company’s robust technology focuses on sports medicine, orthopedic, and maxillofacial fixation.

Announcement

Entirety Biomedical fixed the $1.2 million deal to upgrade first-in-human clinical trials. The financial round was supervised by NuFund Venture Group, while Revere Partners, American Society of Plastic Surgeons, Mass Medical Angels, Community Equity Partners, Michigan Rise, and Union Heritage were the participants.

Entirety In-Progress

The company is establishing a strong portfolio and putting efforts to justify its recent investment and bring more trust of the leaders to its focus area, such as absorbable magnesium implant systems. The system will be powered up with its trademarked Curasorb alloy. The alloy holds full strength to meet the suitable surgeons' call for the traditional titanium implants and the good absorption after the healing.

Entirety’s main aim of the entire study is on the maxillofacial fixation system and lower extremity, in which absorbable implants can prove their capability to replace permanent metal hardware. The company is not following basics; it's attempting something bold and different by establishing non-coated plate-and-screw implant systems.

The systems are engineered to smoothly fit and stay cooperative in the existing surgical operations. The best-in-class technology platform is planned to contribute to maxillofacial and orthopedic applications. Aligning to this, the Curasorb will arise as a capable, supportive, accurate, cosmetic-enabled and standardised bone fixation.

To compete in this vast healthcare sector, the company prioritize and concentrates on staying in contact with smart partners and surgeons. With this Entirety, will get a full-fledged knowledge and a broad view of rapid implant needs. Steadily, after the company’s first preclinical study completion, confidence in the upcoming investment has doubled.

CEO and Co-Founder of Entirety Biomedical, Jake Edick, said, “There has to be a clear path for the healing without any disruption of secondary removal procedures and complications in the implant. We’re dusting out the hurdles in absorbable implants, providing surgeons the best options for the permanent hardware with the same cost, reimbursement and procedures specification that they are aware.

“Our mission is to introduce a new term of the orthopedic fixation for quick and easy healing of patients to dodge trauma of permanent hardware in the body."